ES2233938T3 - Chaperonina 10. - Google Patents

Chaperonina 10.

Info

Publication number
ES2233938T3
ES2233938T3 ES95902003T ES95902003T ES2233938T3 ES 2233938 T3 ES2233938 T3 ES 2233938T3 ES 95902003 T ES95902003 T ES 95902003T ES 95902003 T ES95902003 T ES 95902003T ES 2233938 T3 ES2233938 T3 ES 2233938T3
Authority
ES
Spain
Prior art keywords
baselineskip
cpn10
epf
protein
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95902003T
Other languages
English (en)
Spanish (es)
Inventor
Halle Morton
Alice Christina Cavanagh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPM8234A external-priority patent/AUPM823494A0/en
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Application granted granted Critical
Publication of ES2233938T3 publication Critical patent/ES2233938T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
ES95902003T 1993-11-30 1994-11-30 Chaperonina 10. Expired - Lifetime ES2233938T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPM270593 1993-11-30
AUPM270593 1993-11-30
AUPM8234A AUPM823494A0 (en) 1994-09-16 1994-09-16 Diagnostic and therapeutic uses of chaperonin 10
AUPM823494 1994-09-16

Publications (1)

Publication Number Publication Date
ES2233938T3 true ES2233938T3 (es) 2005-06-16

Family

ID=25644587

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95902003T Expired - Lifetime ES2233938T3 (es) 1993-11-30 1994-11-30 Chaperonina 10.

Country Status (11)

Country Link
US (3) US6113899A (enExample)
EP (2) EP0731811B1 (enExample)
JP (3) JP3987104B2 (enExample)
AT (1) ATE282634T1 (enExample)
AU (2) AU684578B2 (enExample)
CA (1) CA2177179C (enExample)
DE (1) DE69434137T2 (enExample)
ES (1) ES2233938T3 (enExample)
NZ (2) NZ276670A (enExample)
PT (1) PT731811E (enExample)
WO (2) WO1995015338A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233938T3 (es) * 1993-11-30 2005-06-16 The University Of Queensland Chaperonina 10.
WO1999002989A1 (en) * 1997-07-10 1999-01-21 Medical Research Council Chaperone fragments
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
DK1399744T3 (da) * 2001-06-27 2008-09-22 Janssen Pharmaceutica Nv EPF-receptorassays, forbindelser og terapeutiske præparater
AU2002952492A0 (en) 2002-11-06 2002-11-21 Cbio Limited Chaperonin 10 immunosuppression
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
JP2007517808A (ja) * 2004-01-16 2007-07-05 キュビオ リミテッド Ｔｏｌｌ様受容体誘導性のサイトカインおよびケモカイン分泌のシャペロニン１０調節
KR20080098579A (ko) * 2005-08-31 2008-11-11 씨바이오 리미티드 변형된 샤페로닌 10
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
KR20080075505A (ko) * 2005-10-20 2008-08-18 씨바이오 리미티드 과민증의 치료 방법
CA2644058C (en) * 2006-03-02 2016-08-09 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
BRPI0911676A2 (pt) 2008-04-11 2016-11-29 Cbio Ltd polipeptídeo cpn10 isolado, ácido nucléico isolado, construção de expressão, célula hospedeira, anticorpo, composição farmacêutica, método para tratar ou prevenir uma doença, método para modular a sinalização do prr, método para modular a produção e/ou a secreção de um ou mais imunomoduladores, método para inibir a produção e/ou a secreção de um ou mais imunomoduladores, método de identificação de um composto que se liga a um polipeptídeo, método para rastrear um coposto e um ligante de prr e variante funcional, derivado, homólogo, análogo ou fragmento do polipeptídeo
CA2776874A1 (en) 2009-10-09 2011-04-14 Cbio Limited Chaperonin 10 variants
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
KR101776013B1 (ko) * 2017-05-26 2017-09-07 (주)넥스젠바이오텍 항산화 활성 및 피부 세포 증식 효과가 증가한 열 충격 단백질 10과 브라제인 단백질의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005498A1 (en) * 1985-03-12 1986-09-25 University Of Queensland Method for detecting early pregnancy factor (epf) in mammals, purifying epf and method for producing a monoclonal antibody
AU599021B2 (en) * 1985-03-12 1990-07-12 University Of Queensland, The Method for detecting early pregnancy factor (epf) in mammals,purifying epf and method for producing a monoclonal antibody
WO1988004779A1 (en) * 1986-12-22 1988-06-30 University Of Queensland Method of treatment of mammals using antibodies to early pregnancy factor (epf)
AU1086988A (en) * 1986-12-22 1988-07-15 University Of Queensland, The Method of treatment of mammals using antibodies to early pregnancy factor (epf)
ES2233938T3 (es) * 1993-11-30 2005-06-16 The University Of Queensland Chaperonina 10.

Also Published As

Publication number Publication date
EP0731811A1 (en) 1996-09-18
AU684578B2 (en) 1997-12-18
US6113899A (en) 2000-09-05
WO1995015338A1 (en) 1995-06-08
NZ276670A (en) 1998-01-26
EP0731811A4 (en) 2003-05-28
EP0731811B1 (en) 2004-11-17
CA2177179C (en) 2006-10-17
EP0733071A4 (en) 1997-02-26
DE69434137T2 (de) 2005-12-01
JP3987104B2 (ja) 2007-10-03
NZ276672A (en) 1998-01-26
AU1103695A (en) 1995-06-19
US6417334B1 (en) 2002-07-09
AU684577B2 (en) 1997-12-18
AU1103495A (en) 1995-06-19
DE69434137D1 (en) 2004-12-23
JP3545408B2 (ja) 2004-07-21
ATE282634T1 (de) 2004-12-15
WO1995015339A1 (en) 1995-06-08
JP2004067698A (ja) 2004-03-04
EP0733071A1 (en) 1996-09-25
JPH09506431A (ja) 1997-06-24
US7358329B2 (en) 2008-04-15
PT731811E (pt) 2005-04-29
JP3986481B2 (ja) 2007-10-03
JPH09505811A (ja) 1997-06-10
US20030175280A1 (en) 2003-09-18
CA2177179A1 (en) 1995-06-08

Similar Documents

Publication Publication Date Title
EP0731811B1 (en) Chaperonin 10
ES2345746T3 (es) Metodos para la eliminacion de amiloide usando anticuerpos antiamiloide.
ES2144424T5 (es) Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige.
EP1051432A2 (en) Method for reducing immunogenicity of proteins
Cavanagh Production in vitro of mouse early pregnancy factor and purification to homogeneity
US5859189A (en) Peptides and polypeptides derived from the submaxillary gland of the rat, corresponding polyclonal and monoclonal antibodies, corresponding hybridomas and uses of these products for diagnosis, for detection or therapeutic purposes
JPH05508847A (ja) 伝達因子および使用方法
ES2351993T3 (es) Inmunosupresión mediante chaperonina 10.
CA2176948C (en) Chaperonin 10
JP2718827B2 (ja) 分泌Ｍａｃ−２結合糖タンパク質
JP2815582B2 (ja) 原発性胆汁肝硬変自己抗原
ES2300625T3 (es) Peptido paralizante de musaraña para uso en terapia neuromuscular.
ES2326324T3 (es) Me-5, me-2 y epp2: antigenos de proteina humana reactivos con anticuerpos presentes en el suero de mujeres que padecen de endometriosis.
NO854167L (no) Antigene peptidforbindelser.
US6387875B1 (en) Method of use for murine leukaemia inhibitory factor-binding protein (mLBP)
Pleau et al. [19] Thymulin
WO1991015236A1 (en) Treatment of autoimmune diseases
JPS61100598A (ja) 抗原性ペプチド化合物
US5661003A (en) Water channel
AU662433B2 (en) Leukaemia inhibitory factor-binding protein
Otto et al. Production of polyclonal antibodies to feline tumor necrosis factor
Naz Cloning and Sequencing of Sperm Antigens Involved in Oocyte Interaction: Clinical applications in infertility and immunocontraception